Camilla Qvortrup

Medicine & Life Sciences

1. Colorectal Neoplasms 100%
2. pembrolizumab 99%
3. Dihydrouracil Dehydrogenase (NADP) 79%
4. Colonic Neoplasms 73%
5. encorafenib 69%
6. Circulating Tumor DNA 58%
7. Medical Oncology 55%
8. Neoplasms 49%
9. Immunotherapy 49%
10. Adjuvant Chemotherapy 49%
11. DNA Mismatch Repair 49%
12. Cetuximab 44%
13. Neoadjuvant Therapy 43%
14. Survival 41%
15. Esophagectomy 41%
16. Physical Fitness 41%
17. Esophageal Neoplasms 36%
18. C-Reactive Protein 31%
19. Therapeutics 30%
20. Risk Assessment 29%
21. Uracil 29%
22. Neutrophils 27%
23. Interleukin-6 27%
24. Biomarkers 26%
25. Meta-Analysis 26%
26. Systematic Reviews 26%
27. Safety 25%
28. Dihydropyrimidine Dehydrogenase Deficiency 25%
29. Lymphocytes 24%
30. Cohort Studies 24%
31. Exercise 22%
32. Quality of Life 22%
33. Progression-Free Survival 21%
34. Recurrence 21%
35. Inflammation 20%
36. Fluorouracil 19%
37. Preclinical Drug Evaluations 13%
38. Population 13%
39. Rectal Neoplasms 13%
40. Cytotoxins 13%
41. Hospitalization 13%
42. Odds Ratio 13%
43. Synthetic Lethal Mutations 12%
44. tegafur-gimeracil-oteracil 12%
45. Genotype 12%
46. Drug Therapy 12%
47. Synthetic Drugs 12%
48. Confidence Intervals 12%
49. Cardiorespiratory Fitness 11%
50. Clinical Trials 10%